MADISON, Wis., Aug. 24, 2017 /PRNewswire/ -- Propeller
Health, a leading digital solution for respiratory medicine, today
announced the expansion of its 2015 collaboration with GSK,
enabling both companies to prepare for and undertake commercial
activities using the Propeller clip-on sensor and software platform
for use with GSK's ELLIPTA Inhaler. The companies will continue
ongoing research and development efforts to collect evidence from
the Propeller clip-on sensor and software platform used in
conjunction with GSK's respiratory medicines for asthma and
COPD.
The announcement follows successful CE marking and US FDA 510(k)
class II clearance of the Propeller sensor and software program for
the ELLIPTA Inhaler, in late 2016. The clip-on sensor for the
ELLIPTA Inhaler automatically records medication use, which the
Propeller platform analyzes and presents to patients and physicians
through its data-driven digital interfaces, providing an in-depth
view into adherence.
"We are excited to be working closely with GSK to make the
sensor for the ELLIPTA inhaler available in our commercial
programs, and for the first time, as part of commercial pilots with
GSK outside the US," said David Van
Sickle, CEO and co-founder of Propeller. "Companion digital
experiences simplify and personalize the management of chronic
respiratory disease, and help ensure individuals and their
physicians realize the benefits of inhaled medicines."
Eric Dube, Senior Vice President
and Head, Global Respiratory Franchise GSK, said: "Digital
innovations, like sensor technologies, will help us ensure patients
receive the best possible package of care management and treatment
for their respiratory condition. We are excited to expand our
collaboration with Propeller as a further step in our journey
towards achieving connected health systems for people with asthma
and COPD."
The Propeller platform has been used by patients and physicians
in over 55 commercial programs across the
United States, including major healthcare systems, payers,
employers and other commercial partners. It is compatible with the
majority of commonly used asthma and COPD inhaler devices including
controller and reliever metered dose inhalers (MDIs), and other
inhaler devices (dry powder inhalers (DPIs) and soft mist inhalers
(SMIs)).
GSK has been a leader in respiratory for over 45 years,
developing new and first-in-class medicines, approaches and
insights which have helped to influence and support the management
of asthma and chronic obstructive pulmonary disease
(COPD). The ELLIPTA inhaler is a platform inhaler device that
is being used by GSK in the development of a range of innovative
medicines across its clinical development portfolio for respiratory
diseases.
About Propeller
Propeller empowers people with asthma
and COPD to live measurably better lives. In 2010 Propeller set out
to modernize respiratory medicine, enable people to minimize the
impact of asthma and COPD on their daily lives, and connect them to
their physicians, environment and community. Propeller's
information-powered approach to respiratory management guides
physicians and patients to the optimal path of therapy for each
individual. With connected inhalers, digital interfaces, and
personalized insights, participants receive personal guidance and
expert direction anytime. Backed by 3M Ventures (NYSE: MMM), SR
One, Hikma Ventures (LON: HIK), Safeguard Scientifics (NYSE: SFE),
Social Capital and other investors, Propeller received the American
Telemedicine Association's 2016 President's Award for Innovation in
Remote Healthcare and was recognized as one of the top "Fierce 15"
medical device companies in 2015 by FierceMedicalDevices. In 2017,
Fast Company named Propeller as one of the most innovative
companies in Health. For more information visit:
www.propellerhealth.com
View original
content:http://www.prnewswire.com/news-releases/propeller-health-announces-expansion-of-digital-health-collaboration-with-glaxosmithkline-to-improve-management-of-asthma-and-copd-300508991.html
SOURCE Propeller Health